Anthem Biosciences posts Q1 FY26 PAT at Rs. 135.8 Cr
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
Rivaroxaban is used to treat venous thromboembolism
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Reinforcing commitment to ethical and sustainable growth
NorUDCA is the first?in?class treatment for Non?alcoholic Fatty Liver Disease (NAFLD) in India
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Subscribe To Our Newsletter & Stay Updated